Sector News

Eli Lilly is expanding its global reach: CEO

October 20, 2016
Life sciences

Eli Lilly is expanding its international operations to target diabetes and tuberculosis in areas without access to proper treatment, CEO John Lechleiter said Tuesday.

Lechleiter told CNBC’s “Squawk Box” the pharmaceutical giant will expand a program already in place to provide parts of Brazil, Mexico, South Africa, and India with treatment for Type 2 diabetes.

Lechleiter, who is stepping down as CEO, president and chairman this year, said the company hopes to reach 30 million people on an annual basis by the year 2030.

Lechleiter, who will stay on as nonexecutive chairman, is being replaced by Senior Vice President Dave Ricks. Lechleiter said Ricks, a longtime employee, will be the “perfect person” to lead the company through the numerous product launches it expects by 2023.

The pharmaceutical giant reports earnings on Oct. 25. Analysts expect $3.59 earnings per share, according to Thomson Reuters.

Source: CNBC

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.